A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia

Nucleic Acids Research

Volumn 39, Issue 6, 2011, Pages 2458-2469

  Mallikaratchy, Prabodhika R ^a   Ruggiero, Alessandro ^a   Gardner, Jeffrey R ^a   Kuryavyi, Vitaly ^b   Maguire, William F ^a   Heaney, Mark L ^a   McDevitt, Michael R ^a   Patel, Dinshaw J ^b   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK STRUCTURAL BIOLOGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN M; LOCKED NUCLEIC ACID; MACROGOL; MULTIVALENT DNA APTAMER; NUCLEASE; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BIOMEDICAL ENGINEERING; CELL INTERACTION; CELL SPECIFICITY; CONTROLLED STUDY; ENZYME STABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN TARGETING;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN M; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MICE; MICE, NUDE; OLIGONUCLEOTIDES; RECEPTORS, ANTIGEN, B-CELL;

EID: 79953706298     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq996     Document Type: Article

References (37)

1. Clarke,C.A., Glaser,S.L., Dorfman,R.F., Bracci,P.M., Eberle,E. and Holly,E.A. (2004) Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol. Biomarkers Prev., 13, 138-143.
2. Winter,M.C. and Hancock,B.W. (2009) Ten years of rituximab in NHL. Expert Opin. Drug Saf., 8, 223-235.
3. Morris,J.C. and Waldmann,T.A. (2009) Antibody-based therapy of leukaemia. Expert Rev. Mol. Med., 11, e29.
4. Petri,A., Lindow,M. and Kauppinen,S. (2009) MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res., 69, 393-395.
5. Braasch,D.A., Constantinescu,Z.P., Ren,G., Oz,O.K., Mason,R.P. and Corey,D.R. (2004) Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett., 14, 1139-1143.
6. Stenvang,J. and Kauppinen,S. (2008) MicroRNAs as targets for antisense-based therapeutics. Expert Opin. Biol. Ther., 8, 59-81.
7. Dassie,J.P., Liu,X.Y., Thomas,G.S., Whitaker,R.M., Thiel,K.W., Stockdale,K.R., Meyerholz,D.K., McCaffrey,A.P., McNamara,J.O. and Giangrande,P.H. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol., 27, 839-849.
8. Tuerk,C. and Gold,L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510.
9. Ellington,A.D. and Szostak,J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
10. Hnatowich,D.J. and Nakamura,K. (2006) The influence of chemical structure of DNA and other oligomer radiopharmaceuticals on tumor delivery. Curr. Opin. Mol. Ther., 8, 136-143.
11. Jayasena,S.D. (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem., 45, 1628-1650.
12. Samaranayake,H., Wirth,T., Schenkwein,D., Räty,J.K. and Ylä-Herttuala,S. (2009) Challenges in monoclonal antibody-based therapies. Ann. Med., 41, 322-331.
13. Kim,Y., Cao,Z. and Tan,W. (2008) Molecular assembly for high-performance bivalent nucleic acid inhibitor. Proc. Natl Acad. Sci. USA, 105, 5664-5669.
14. McNamara,J.O., Kolonias,D., Pastor,F., Mittler,R.S., Chen,L., Giangrande,P.H., Sullenger,B. and Gilboa,E. (2008) Multivalent 4-1BB binding aptamers costimulate CD8+T cells and inhibit tumor growth in mice. Clin. Investig., 118, 376-386.
15. Dollins,C.M., Nair,S., Boczkowski,D., Lee,J., Layzer,J.M., Gilboa,E. and Sullenger,B.A. (2008) Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol., 15, 675-682.
16. Tang,Z., Shangguan,D., Wang,K., Shi,H., Sefah,K., Mallikratchy,P., Chen,H.W., Li,Y. and Tan,W. (2007) Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem., 79, 4900-4907.
17. Mallikaratchy,P., Tang,Z., Meng,L., Shangguan,D., Kwame,S. and Tan,W. (2007) Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol. Cell. Proteomics, 6, 2230-2238.
18. Furst,D.E. (2009) Serum immunoglobulins and risk of infection: how low can you go? Semin. Arthr. Rheum., 39, 18-29.
19. Irish,J., Czerwinski,D.K., Garry,P., Nolan,X.R. and Levy,R. (2006) Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor infiltrating nonmalignant B cells. Blood, 108, 3135-3142.
20. Herzog,S., Reth,M. and Jumaa,H. (2009) Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signaling. Nat. Rev. Immunol., 9, 195-205.
21. Zuker,M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 13, 3406-3415.
22. Mallikaratchy,P., Tang,Z. and Tan,W. (2008) Cell specific aptamer photosensitizer conjugates as a molecular tool in photodynamic therapy. Chem. Med. Chem., 3, 425-427.
23. Hicke,B.J., Marion,C., Chang,Y.F., Gould,T., Lynott,C.K., Parma,D., Schmidt,P.G. and Warren,S. (2001) Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem., 276, 48644-48654.
24. Schmidt,K.S., Borkowski,S., Kurreck,J., Stephens,A.W., Bald,R., Hecht,M., Friebe,M., Dinkelborg,L. and Erdmann,V.A. (2004) Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res., 32, 5757-5765.
25. Shangguan,D., Tang,Z., Mallikaratchy,P., Xiao,Z. and Tan,W. (2007) Optimization and modifications of aptamers selected from live cancer cell lines. Chembiochem, 8, 603-606. (Pubitemid 47194848)
26. Kaur,H., Babu,B.R. and Maiti,S. (2007) Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem. Rev., 107, 4672-4697. (Pubitemid 350225863)
27. Cambier,J.C. and Campbell,K.S. (1992) Membrane immunoglobin and its accomplices: new lessons from an old receptor. FASEB J., 6, 3207-3217.
28. Rogers,J., Early,P., Carter,C., Calame,K., Bond,M., Hood,L. and Wall,R. (1980) Two mRNAs with different 3 ends encode membrane-bound and secreted forms of immunoglobulin chain. Cell, 20, 303-312.
29. Friedlander,R.M., Nussenzweig,M.C. and Leder,P. (1990) Complete nucleotide sequence of the membrane form of the human IgM heavy chain. Nucleic Acids Res., 18, 4278.
30. Meerten,T.V. and Hagenbeek,A. (2010) CD20-targeted therapy: the next generation of antibodies. Semin. Hematol., 47, 199-210.
31. Thielemans,K., Maloney,D.G., Meeker,T., Fujimoto,J., Doss,C., Warnke,R.A., Bindl,J., Gralow,J., Miller,R.A. and Levy,R. (1984) Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. J. Immunol., 133, 495-501.
32. Joshi,A., Vance,D., Rai,P., Thiyagarajan,A. and Kane,R.S. (2008) The design of polyvalent therapeutics. Chem. Eur. J., 14, 7738-7747.
33. Albrecht,H. and DeNardo,S.J. (2006) Recombinant Antibodies: from the laboratory to the clinic. Cancer Biother. Radiopharmaceut., 21, 285-304.
34. Garanger,E., Boturyn,D. and Dumy,P. (2007) Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med. Chem., 7, 552-558.
35. Scheinberg,D.A., Villa,C.H., Escorcia,F.E. and McDevitt,M.R. (2010) Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat. Rev. Clin. Oncol., 7, 266-276.
36. Longmire,M., Choyke,P.L. and Kobayashi,H. (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine, 3, 703-717.
37. Krolick,K.A. and Wisnieski,B.J. (1977) Sercarz, EE. Differential leteral mobility of IgM and IgG receptors in mouse B lymphocyte membranes. Proc. Natl Acad. Sci. USA, 74, 4595-4599.